Yesterday, 340B Report broke the news that a group of 25 states from blue bastions such as Connecticut and Maryland to red states such as Arkansas and Mississippi weighed in favor of the federal government’s effort to punish drug manufacturer for restricting the use of the 340B program in the contract pharmacy setting. Today, we take a deeper dive into the arguments that 25 state attorneys general made in federal court filings yesterday.
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
